License out burst! Cinda rabid 4 transactions a number of well-known pharmaceutical companies involved

In 2020, licensing transactions surged from the previous year, with outlicense transactions approaching the whole of 2018, and behind the hot deals, Hengrui Pharma announced a joint termination project!, following a $1.5 billion license-out deal with Lilly, on June 9th Cinda Bio re-entered roche with a $2 billion research and development strategy that covers multiple tumor cell therapies and bispecific antibodiesMeanwhile, Corning-Jerry announced a strategic clinical partnership with Sanofi on HER2-positive breast cancersuch as the aforementioned local innovative pharmaceutical companies and foreign pharmaceutical companies cooperation cases more and more, and in May and June there is a trend of outbreaks, in which license-out once again refreshed China's speed, five-month trading events have reached the whole of 2018But after the transaction, it is not necessarily possible to go to the other side, Hengrui Pharmaceuticals recently 2 drugs co-operative termination is a good examplein recent years, there have been more and more cases of cooperation between local pharmaceutical companies and foreign pharmaceutical companies on new drugsAs of June 9, 2020, there were 25 new drug licensing transactions between local and foreign pharmaceutical companies, close to the number of such transactions for the whole of 2019, according to E drug managersuntil now, License in trading has been the normIn recent years, the number of new drug deals has increased, and 2018 is considered the year of the License out explosionAccording to the statistics of the new kang industry, in 2018 there were 9 license out transactions in China, in which the authorized party involved Hengrui Pharmaceuticals, Haussen Pharmaceuticals, Tianshili, Fuhong Hanxuan, Columbotai and other large companiesbut predictably, this year's big odds are to catch up with 2018 as the real License Out yearWhat's more, license out trading is beginning to show signs of parity with License inAs of June 9, 2020, the number of license out transactions in China has reached eight, close to the 13 cases in the whole of 2018, according to E Drug Managersdata sources: public information collated, sorted by amount, some of the amounts not disclosed
from the authorized companies, compared to 2019 forward, 2020 is mostly old faces, very few are new facesHengrui Pharmaceuticals, FuHong Hanxuan as a regular visitor to exist, Junshi creatures as a "new" to join the Sinda as the representative of the local new camp, Corning Jerry after the end of last year appeared on the list, re-emergedIt is worth mentioning that the majority of the licensed trading calendar year list, are listed pharmaceutical companies, but in recent years began to appear some non-listed pharmaceutical companieson June 1 this year, MrGarcorse struck an enabling deal with AbbVie as a representative of the unlisted innovative pharmaceutical companyUnder the agreement, the two companies will jointly develop and commercialize the protein tyrosine phosphatase (SHP2) inhibitors that act on key targets for cancer cells and immune cells, and AbbVie will receive exclusive license sedativerights to the Garcos SHP2 projectThe financial terms of the transaction were not disclosed by the partiesin addition, in recent years, the authorized transaction of new drugs also extended to innovative pharmaceutical industry chain enterprises, Chengdu pilot became the representative of this directionAccording to the data, Chengdu Pilot is a CRO company that provides research and development services during the early detection phase of drugs, as well as the transfer of new drug research and development projects, with more than 400 billion DNA-coded small molecule compoundsThis year has reached a new drug research and development transfer agreement with Japan's scientific researchCo., Ltdand Tianbian Sanling Pharmaceuticals, mainly involving a series of new structure of small molecular pilot compounds, the specific target is designated by the transaction party undisclosed targetIn 2017, the company has also partnered with MNC, including Mercado, Johnson and Johnson, Bayer and Takedafrom the authorized parties, previously the transaction object is more in favor of such as Roche, Sanofi, Lilly and other MNc, but the last two years of trading objects are no longer limited to MNC, began to diversifyIn addition to the United States, Japan, South Korea, Europe and other popular regionsOverall, whether it is a significant increase in trading frequency, or the expansion of trading scope, object, all reflect that China's new drug research and development is more and more in line with the internationalfrom the authorized product area, only Pumei San Pharmaceuticals, Genesis Bio, Hong Kong Tylenol involved in a few transactions do not involve tumorsTwo other outbreak-related projects are juniper Bio's $255 million new crown antibody program, and Fosun Pharma's $85 million vaccine program for BioNTechIn addition, the rest of the trading products come from the field of cancer immunity , in the field of tumor immunity, bispecific antibodies are receiving more and more attention In addition to the above-mentioned Cinda's collaboration with Roche, Corning And Sanofi, which involved bispecific antibodies, Dinghang Pharma introduced a bispecific antidotic antibody that is resistant to DLL4/VEGF Previously, bispecific antibodies were subject edayating by various factors such as technology, so most of the drugs in the study of BsAb are now in the early stages As of March 2019, there are more than 20 different commercial technology platforms available for BsAb development worldwide, and more than 100 BsAb drugs are in the research phase, most of them in the preclinical and clinical phase I phases, according to Nature data from the first half of this year, the occurrence of various cases in The First Half of this year, January by the holiday and other factors affected by the occurrence of 4 transactions, In February by the impact of the outbreak did not occur, in March began to pick up, in May transactions reached 7, began to show the trend of outbreaks, and there is a sustained trend As of june, there had been three such transactions, two of which were new On June 9, , Cinda Announced a partnership of about $2 billion with Roche Under the agreement, the partnership will focus on research, clinical development and commercialization of multiple bispecific antibody (BsAb) and cell therapy (CAR-T) products, which will be used directly for blood and solid tumor treatment In addition to this transaction, Cinda Bio has reached four such cooperation in 2020, becoming the most frequently traded company at the same time, Corning-Jerry announced a strategic partnership with Sanofi to jointly promote clinical trials of KN026 and Dositacy injections for PATIENTs with HER2-positive breast cancer Under the terms of the agreement, Sanofi will have the right to negotiate an exclusive right to introduce KN026 within the exclusive period of time after reaching a specific clinical milestone KN026 is an anti-HER2 bispecific antibody, can be combined with TWO non-overlapping epitopes of HER2, resulting in the double HER2 signal blocking, presumably causing HER2 to accumulate on the cell surface and swallow Dositatha injection is a microtube inhibitor that inhibits the growth and spread of cancer cells in the body note that both recent transactions involved bispecific antibodies Bispecific antibodies are artificial antibodies containing 2 specific antigen binding sites, which are more specific than single antibody binding, and are less likely to have off-target effects and exhibit higher efficacy since joining ICH in June 2017, , the domestic drug regulatory system has become more and more in line with international standards, and with the approval of innovative drugs increasingly fast, China's biopharmaceuticals are already integrating into the international market and driving the increase in trading the surge in figures is encouraging, but it's hard to ignore the risks involved in new drug development, whether it's inlicense in or license out, and even research and development leaders such as Hengrui Pharmaceuticals can't be avoided Recently, there have also been a number of cases of termination of cooperation, the reasons from strategy, product adjustment and so on On June 10, , Hengrui announced its decision to terminate its cooperation with TelomelysinTM (OBP-301), a product of adenovirus The reason is the adjustment of research and development strategy the cooperation began on November 30, 2016 The agreement provides that Oncolyse Japan will transfer the exclusive license rights to the development, production and commercialization of The AdheliasTM (OBP-301) in the Chinese mainland, Hong Kong and Macao Special Administrative Regions for a fee not exceeding US$102 million , Hengrui Pharmaceuticals believes that because of the indivisibility between tumor virus and anti-tumor immunology mechanism, the market development of tumor virus will continue to expand with the continuous deepening of tumor immunology research The combination of the lysoma virus with other immunotherapy drugs will be a major direction in the future The introduction of this product is a good complement to HengRui's existing cancer immunoproduct product line, which will provide more choices for HengRui to seek new treatments in the field of cancer, thereby enhancing the competitiveness of Hengrui's anti-tumor field Prior to the termination of , Hengrui Pharmaceuticals had conducted preclinical studies of the ademotic adenovirus product TelomelysinTM in China to other tumor immunotherapy, tumor virus has the advantages of high kill efficiency, good targeting, small side effects and low cost There are only two cancer drugs currently on the market worldwide: one is Ankeri (recombinant human type 5 adenovirus, developed by the current Cinda Bio founder Yu Dechao), was approved for domestic listing in April 2005, mainly for the treatment of advanced nasopharyngeal cancer, and the other is T-vec, approved by the FDA in October 2015 for the treatment of advanced melanoma another advantage was discovered after the PD-1 heat, i.e in conjunction with PD-1 to solve the problem of low tumor response rate Because the tumor virus can be selectively replicated in tumor cells, the "cold" tumor becomes "hot", enhances the immunogenicity of the tumor microenvironment, improves the immune response, and is expected to become an effective combination of immunocheckpoint inhibitors such as PD-1 In a 2017 cell journal, a first injection of the tumor virus (T-VEC) was used in an intravenous trial of PD-1 anti-tumor drugs (K drugs), with a tumor remission rate of up to 62%, of which 33% was full remission it is worth noting that Hengrui Pharma's PD-1 products are complementary to the solution virus products, so the termination of cooperation may be due to the progress of research and development in addition to Hengrui Pharmaceuticals, Tianshili is also actively layout of tumor virus products, unlike Heng Rui, Tianshili signed an irrevocable agreement On May 12, 2020, Tianshili introduced an exclusive development, registration, production and commercialization interest in Chinese mainland, Hong Kong, China and Macau, China, as well as irrevocable and non-exclusive interests in clinical trials in North America and European countries, from Takara Bio, Japan, for $27.5 million in fact, in addition to the above transactions, Tinseli laid out earlier on the tumor virus In 2016, Tianshili purchased the intellectual property rights of the French Transgene pox virus solubility virus vector for 17.89 million yuan and, in July 2018, obtained all research, development and commercial rights for the tumor virus T601 in Greater China in addition to Hengrui and Tianshili two pharmaceutical companies, according to the statistics of medical customers, including Kanghong Bio, Lepu Medical, Li's big pharmaceutical factory, 3D biology, including more than 10 enterprises from overseas to introduce the solution virus project In addition, there are also domestic enterprises including Funojian, Binhebio, Yuan Song Biology and other enterprises in independent research and development to carry out clinical trials, currently more than 200 kinds of tumor virus international, including Johnson and Johnson, AZ, BMS, Amgen and other well-known MNC has been authorized to deal or acquire the way to participate in this field of research and development work source: Pharmaceuticals Online the termination of this transaction is not the first time that Hengrui Pharmaceuticals has On August 10, 2018, HengRui announced the termination of a partnership with Rolapiit, a patented anti-spitting drug for tumor-assisted therapy The original cooperation agreement was concluded on July 29, 2015 between Heng Rui and Tesaro, at which time HengRui was authorized to be responsible for the clinical development, registration and marketing of the drug in China To this end, Hengrui also paid down payments and other related expenses totalling approximately $1.62 million a little further, on February 14, 2018, HengRui announced the termination of its agreement to develop PD-1 monoclonal antibody SHR-1210 in cooperation with Incyte The agreement was signed on 2 September 2015, although unlike the suspended deal, which is a deal that Hengrui has granted to Incyte, which has been refused to continue cooperating for a number of reasons for clinical progress as a domestic pharmaceutical enterprises " research and development of a brother", Hengrui in the past in the self-research products on the road has been a smooth sailing, major new drug varieties are also frequent, but in the last two license in transactions are finally folded, can be seen in the internal research and development and external introduction is still very different When introducing these early products externally, there may be more judgment required.